{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:13:02Z","timestamp":1788455582290,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xops.2026.101090","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:49:11Z","timestamp":1769672951000},"page":"101090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec"],"prefix":"10.1016","volume":"6","author":[{"given":"M Dominik","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-5309","authenticated-orcid":false,"given":"Isabelle","family":"Audo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gaucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9272","authenticated-orcid":false,"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-1510","authenticated-orcid":false,"given":"Line","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3776-1367","authenticated-orcid":false,"given":"Stephen","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-911X","authenticated-orcid":false,"given":"Katarina","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rousso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8176-4638","authenticated-orcid":false,"given":"Rainer","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1557","authenticated-orcid":false,"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-6980","authenticated-orcid":false,"given":"Aaron","family":"Nagiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-2081","authenticated-orcid":false,"given":"Bart P.","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101090_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810513","article-title":"RPE65 c.353G>A, p.(Arg118Lys): a novel point mutation associated with retinitis pigmentosa and macular atrophy","volume":"23","author":"Bjelos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xops.2026.101090_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ophtha.2010.09.005","article-title":"Fundus albipunctatus associated with compound heterozygous mutations in RPE65","volume":"118","author":"Schatz","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101090_bib4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/ejhg.2011.86","article-title":"A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement","volume":"19","author":"Bowne","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.xops.2026.101090_bib5","article-title":"RPE65 variant p.(E519K) causes a novel dominant adult-onset maculopathy in 83 affected individuals","author":"Van Vooren","year":"2025","journal-title":"Res Sq"},{"key":"10.1016\/j.xops.2026.101090_bib6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101090_bib7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ejhg.2015.241","article-title":"Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in leber congenital amaurosis in Denmark","volume":"24","author":"Astuti","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.xops.2026.101090_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/iovs.63.2.13","article-title":"RPE65-Associated retinopathies in the Italian population: a longitudinal natural history study","volume":"63","author":"Testa","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101090_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","article-title":"The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene","volume":"199","author":"Chung","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical perspective: treating RPE65-Associated retinal dystrophy","volume":"29","author":"Maguire","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.xops.2026.101090_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061080","article-title":"Narrative medicine to investigate the quality of life and emotional impact of inherited retinal disorders through the perspectives of patients, caregivers and clinicians: an Italian multicentre project","volume":"12","author":"Simonelli","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.xops.2026.101090_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101090_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-Mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101090_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-Mediated leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101090_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2022.06.018","article-title":"Inflammation after voretigene neparvovec administration in patients with RPE65-Related retinal dystrophy","volume":"129","author":"Kessel","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101090_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101090_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.2.13","article-title":"Chorioretinal atrophy growth after voretigene neparvovec retinotopically is connected to retinal functional rescue","volume":"13","author":"Stingl","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101090_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101115","article-title":"Therapy with voretigene neparvovec. How to measure success?","volume":"92","author":"Stingl","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101090_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.2038","article-title":"Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence","volume":"10","author":"Kolesnikova","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.xops.2026.101090_bib22","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/biom13101484","article-title":"Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-Mediated inherited retinal dystrophies in a cohort of patients from a single center","volume":"13","author":"Kiraly","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.xops.2026.101090_bib23","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/IAE.0000000000003576","article-title":"Retinal pigment epithelium atrophy after subretinal voretigene neparvovec-rzyl for RPE65-Related disease: a 6-Month Follow-Up","volume":"42","author":"Giansanti","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101090_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","article-title":"Visual acuity, retinal morphology, and patients' perceptions after voretigene neparovec-rzyl therapy for RPE65-Associated retinal disease","volume":"6","author":"Sengillo","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101090_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22180-6","article-title":"Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy","volume":"12","author":"Testa","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2026.101090_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oret.2023.08.017","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-rzyl for RPE65-Mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101090_bib27","article-title":"Could internal limiting membrane peeling before voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?","volume":"10","author":"Dormegny","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.xops.2026.101090_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.xops.2026.101090_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.13.6.11","article-title":"Perimacular atrophy following voretigene neparvovec-rzyl treatment in the setting of previous contralateral eye treatment with a different viral vector","volume":"13","author":"Ku","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101090_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","article-title":"Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 mutation-associated inherited retinal degeneration in a clinical setting","volume":"131","author":"Lorenz","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101090_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.oret.2024.01.021","article-title":"Objective outcomes to evaluate voretigene neparvovec treatment effects in clinical practice","volume":"8","author":"Melillo","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101090_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bjo-2024-326221","article-title":"12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy","volume":"109","author":"Daruich","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41434-021-00294-2","article-title":"Injection pressure levels for creating blebs during subretinal gene therapy","volume":"29","author":"Scruggs","year":"2022","journal-title":"Gene Ther"},{"key":"10.1016\/j.xops.2026.101090_bib34","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.2147\/OPTH.S231804","article-title":"Voretigene neparvovec in retinal diseases: a review of the current clinical evidence","volume":"14","author":"Gao","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101994","article-title":"Metabolic plasticity in a Pde6b(STOP\/STOP) retinitis pigmentosa mouse model following rescue","volume":"88","author":"Ayten","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.xops.2026.101090_bib36","first-page":"626","article-title":"The clinical features of retinal disease due to a dominant mutation in RPE65","volume":"22","author":"Hull","year":"2016","journal-title":"Mol Vis"},{"key":"10.1016\/j.xops.2026.101090_bib37","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2026.101090_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11095-018-2564-5","article-title":"Adeno-associated viral gene therapy for inherited retinal disease","volume":"36","author":"Ong","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.xops.2026.101090_bib39","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1111\/aos.15765","article-title":"A morphometric analysis of the retinal arterioles with adaptive optics imaging in RPE65-associated retinal dystrophy after treatment with voretigene neparvovec","volume":"102","author":"Kortuem","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib40","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1073\/pnas.130110497","article-title":"Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration","volume":"97","author":"Mata","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2026.101090_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1523\/JNEUROSCI.21-01-00053.2001","article-title":"The Rpe65 Leu450Met variation increases retinal resistance against light-induced degeneration by slowing rhodopsin regeneration","volume":"21","author":"Wenzel","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.xops.2026.101090_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.preteyeres.2011.11.001","article-title":"The susceptibility of the retina to photochemical damage from visible light","volume":"31","author":"Hunter","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101090_bib43","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s12276-020-0460-7","article-title":"Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy","volume":"52","author":"Taveau","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.xops.2026.101090_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjo-2022-321488","article-title":"Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy","volume":"107","author":"Lopez","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib45","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","article-title":"Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial","volume":"29","author":"MacLaren","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.xops.2026.101090_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2022.02.013","article-title":"Three-year safety results of SAR422459 (EIAV-ABCA4) gene therapy in patients with ABCA4-Associated Stargardt disease: an open-label dose-escalation phase I\/IIa clinical trial, cohorts 1-5","volume":"240","author":"Parker","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101090_bib47","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101090_bib48","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1038\/s41467-024-51575-4","article-title":"Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1\/2 trial","volume":"15","author":"Kvanta","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.xops.2026.101090_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.xops.2026.101090_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100516","article-title":"Dose-dependent progression of chorioretinal atrophy at the injection site after subretinal injection of rAAV2\/8 in Nonhuman Primates","volume":"4","author":"Seitz","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2026.101090_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0140-6736(24)02812-5","article-title":"Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study","volume":"405","author":"Michaelides","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101090_bib52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtm.2023.02.006","article-title":"Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution","volume":"28","author":"Ducloyer","year":"2023","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452600028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452600028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:19:43Z","timestamp":1776241183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266691452600028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S266691452600028X"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101090","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101090"}}